Signos Inc. announced today results from a real-world study demonstrating that adults with obesity without diabetes who actively engaged with the Signos System ? a digital metabolic health platform ...

Key Points Interested in Teladoc Health, Inc.? Here are five stocks we like better. With the GLP-1 agonist market still ...

Celebrity ambassadors in pharma and medtech herald a new dawn of direct-to-consumer advertising.

DexCom DXCM received FDA clearance for its Stelo Glucose Biosensor System for use in children aged two years and older who do not use insulin. The clearance expands access to the company’s ...

Natera delivers robust revenue growth, raising 2026 guidance to $2.74–$2.82 billion, but remains unprofitable. Read more on ...

The wearable patch market is estimated at roughly $ 13- $15 billion in 2026 and is expected to reach the low-twenties of ...

This partnership marks another addition to the growing list of high-profile collaborations between the consumer health and life science sectors.

Moximed, an innovative medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced the publication of five-year MISHA Knee System data ...

The Irish wing speaks to The 42 about recent news, and ‘living the dream’.

A consolation score by former Howe Harlequins tighthead prop Molly Poolman during Scotland’s 41-14 loss away to Italy in ...

June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...

The CONNECT trial, presented at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans, found that 82% of adults with type 2 diabetes who used a Dexcom G7 improved their blood ...